Archin, N M <br/><br/>
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.  [electronic resource] 

 -  Nature  Jul 2012 
 - 482-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-4687 
<br/><br/><label>Standard No.: </label>10.1038/nature11286  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylation--drug effects<br/>Anti-HIV Agents--therapeutic use<br/>Biomarkers--metabolism<br/>CD4-Positive T-Lymphocytes--cytology<br/>Gene Expression Regulation, Viral--drug effects<br/>HIV Infections--blood<br/>HIV-1--drug effects<br/>Histone Deacetylase Inhibitors--administration & dosage<br/>Histones--drug effects<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Proviruses--drug effects<br/>RNA, Viral--biosynthesis<br/>Risk Assessment<br/>Up-Regulation--drug effects<br/>Viremia--drug therapy<br/>Virus Latency--drug effects<br/>Vorinostat